Aquestive Therapeutics, Inc.
AQSTAquestive Therapeutics is a pharmaceutical company specializing in the development and manufacturing of complex molecule delivery systems that serve as alternatives to invasive standard-of-care therapies.
Earnings
Next report
Nov 4, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Aquestive Therapeutics is a pharmaceutical company specializing in the development and manufacturing of complex molecule delivery systems that serve as alternatives to invasive standard-of-care therapies. The company leverages its proprietary PharmFilm and AdrenaVerse technologies to create oral films and prodrug formulations designed for rapid absorption and ease of administration. Their business model combines internal product development with strategic manufacturing and licensing partnerships for global commercialization.
Aquestive is a global leader in oral film drug delivery, having manufactured the majority of the world's prescription oral films.
FAQ
- What is Aquestive Therapeutics, Inc.'s market cap?
- Aquestive Therapeutics, Inc. (AQST) has a market capitalization of $603.7M and trades on NASDAQ.
- What is Aquestive Therapeutics, Inc.'s revenue and profitability?
- Aquestive Therapeutics, Inc. generated $54.1M in trailing twelve-month revenue with a net loss of $78.2M, representing a net margin of -144.6%. Gross margin stands at 67.0%, with free cash flow of -$45.9M. The latest reported period is Q2 2026.
- Who are Aquestive Therapeutics, Inc.'s competitors?
- Aquestive Therapeutics, Inc.'s key competitors include ARS Pharmaceuticals, Inc., Viatris Inc., Indivior PLC, and others. These companies compete in similar markets and product categories.
- Where is Aquestive Therapeutics, Inc. headquartered?
- Aquestive Therapeutics, Inc. is headquartered in United States of America and employs approximately 135 people. It has been publicly traded since 2018.
